Listed, licensed and injuncted: How Incyte is guarding ruxolitinib in the patent’s final months
This post draws on “Injunctions in pharma: Ex parte relief near expiry (ruxolitinib), and API supplier listings and stockpiling as
This post draws on “Injunctions in pharma: Ex parte relief near expiry (ruxolitinib), and API supplier listings and stockpiling as
This post draws on “Biologics and Biosimilar Litigation 2026: Lessons from India, the UPC, Europe and the USA”, presented by
This post draws on “Biologics and Biosimilar Litigation 2026: Lessons from India, the UPC, Europe and the USA”, presented by